Mitratapide
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 2-[(2R)-Butan-2-yl]-4-[4-[4-[4-[[(2S,4R)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one | |
| Clinical data | |
| Trade names | Yarvitan |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 179602-65-4 |
| ATCvet code | QA08AB90 |
| PubChem | CID 213047 |
| UNII | FVW7T75XP4 |
| Synonyms | Mitratapid; R103757 |
| Chemical data | |
| Formula | C36H41ClN8O4S |
| Mol. mass | 717.28 g/mol |
Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.[1] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[2]
The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.
[edit] References
- ^ Mitratapide, vetstream.com
- ^ Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary research communications 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2776940/.
|
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
